Clinical Oncology Portfolio Pathway evidence must prove consultant-level practice across radiotherapy, systemic anti-cancer therapy, acute oncology, tumour-site MDT work, patient communication, appraisal, MSF, patient feedback, safety and quality improvement. This is not a generic oncology route: radiotherapy capability is central.
What makes this specialty different?
What assessors are really testing
The GMC Clinical Oncology SSG says the curriculum is structured across 19 Capabilities in Practice. Assessors are not simply asking whether you have worked as an oncologist. They are checking whether your current evidence proves the professional capabilities of a UK consultant clinical oncologist.
The crucial point is that UK Clinical Oncology includes both radiotherapy and systemic therapies. If your background separates those functions differently, your evidence must still cover the UK clinical oncology curriculum.
How Clinical Oncology evidence should read
A good Clinical Oncology Portfolio Pathway application should read like a current UK consultant practice file. It should not rely on historical training certificates, broad statements of experience, or repeated clinic letters from one tumour site. The written explanation around the evidence needs to make clear what role you played, what decision you made, who supervised or observed the work, how the case maps to the Clinical Oncology curriculum, and whether the evidence is current enough to show maintained capability.
That matters because Clinical Oncology is a combined modality specialty in the UK. Assessors need to see that you can work across radiotherapy, SACT, acute oncology, MDT decision making, complex communication, patient safety, and service improvement. A portfolio that is strong in one of those areas but silent in another can feel clinically senior without proving the whole specialty.
For NHS doctors already working at senior SAS, Specialist, Locum Consultant or fixed-term Consultant level, the challenge is often not lack of experience. It is lack of packaging. Your current work may already include treatment planning, toxicity management, MDT decisions, patient discussions and governance activity, but if those activities are not mapped clearly to the CiPs, they may not carry the weight they should.
For the wider evidence framework, read the Portfolio Pathway overview, the four GMC domains, the structured CV guide, the MSF plan, the audit guide, the reflective practice guide and the structured reports guide.
The mistake to avoid
Do not submit a general oncology portfolio that treats radiotherapy as a side note. For Clinical Oncology, the evidence has to show radiotherapy planning, treatment decision making, delivery, peer review, toxicity management and integration with systemic therapy.
Evidence expectations
The Clinical Oncology SSG gives a detailed evidence framework rather than one simple number. The practical task is to cover each CiP with current, directly relevant evidence and avoid uploading duplicated or poorly mapped documents.
For SEO and, more importantly, for the reader, this section deserves more than a table. Clinical Oncology applicants are often trying to answer practical questions such as: "Is my radiotherapy evidence recent enough?", "Does my SACT work prove consultant-level decision making?", "Will older overseas training count?", and "How do I show that I work safely across tumour sites?" The answer is rarely one single document. It is usually a combination of case-based evidence, workplace observation, structured reports, patient feedback, reflective writing, appraisal and governance evidence.
When building the portfolio, think in evidence bundles rather than isolated uploads. A radiotherapy case might include the clinical context, planning evidence, contouring or treatment plan discussion, peer review, clinic correspondence, toxicity review, reflection and supervisor comment. A SACT case might include the indication, regimen choice, consent discussion, prescription review, dose modification, toxicity management, response assessment and MDT context. The stronger the bundle, the easier it is for an assessor to see genuine consultant-level practice.
What to plan around
Radiotherapy evidence
This is the section that makes Clinical Oncology distinct. Strong evidence shows not only that you understand radiotherapy, but that you can use it safely in real clinical decision making.
Why radiotherapy evidence carries so much weight
Radiotherapy evidence is often the clearest divider between a generic oncology portfolio and a genuine Clinical Oncology Portfolio Pathway application. In the UK, clinical oncologists are expected to understand treatment intent, immobilisation, imaging, target volume definition, organs at risk, dose and fractionation, consent, peer review, treatment verification, on-treatment review, toxicity and late effects. The portfolio does not need to become a physics textbook, but it does need to show that radiotherapy is part of your current clinical judgement.
That means treatment plans and screenshots alone are rarely enough. A strong piece of radiotherapy evidence explains the clinical problem, the patient factors, the MDT recommendation, the radiotherapy technique, the safety checks, the discussion with the patient, the toxicity risks and the follow-up plan. If another consultant has reviewed the work, the evidence should make that explicit.
Doctors trained outside the UK may need to be especially careful here. In some systems, radiotherapy and systemic oncology are separated differently. If your previous role was mostly chemotherapy or clinic-based oncology, you may need a UK post that gives real radiotherapy planning, peer review and on-treatment review exposure before a Portfolio Pathway application is realistic.
Radiotherapy evidence that earns its place
Assessors should be able to see planning, treatment intent, peer review, toxicity and patient-centred decision making.
Contouring and treatment design
Use treatment plans, contours, dosimetry discussions, site-specific protocols and consultant feedback.
On-treatment review and toxicity
Show how you monitor response, manage toxicity, adapt treatment and communicate risk.
Quality and safety
Include radiotherapy peer review, protocol use, governance and learning from complex decisions.
Radiotherapy plus SACT
Show how you integrate radiotherapy with systemic therapies, surgery, imaging and pathology.
SACT, acute oncology and MDT work
Clinical Oncology also needs strong evidence of systemic anti-cancer therapy, acute oncology and MDT decision making. The key is to show clinical reasoning, not just attendance.
Showing safe systemic therapy and acute oncology practice
SACT evidence should not simply show that you have attended clinics where systemic treatment was discussed. It should show that you can choose, explain, prescribe, monitor and modify systemic treatment safely. The best evidence demonstrates how you weigh disease biology, performance status, co-morbidity, previous treatment, patient preference, clinical trial options and treatment intent.
Acute oncology evidence is equally important because it shows how you manage cancer and treatment-related complications under pressure. Strong examples include neutropenic sepsis, spinal cord compression, immunotherapy toxicity, superior vena cava obstruction, hypercalcaemia, treatment-related organ toxicity, new cancer presentations, MUO/CUP work-up and complex ceilings-of-care discussions.
Where possible, link SACT and acute oncology evidence back to MDT decisions, clinic letters, ward reviews, escalation plans, treatment protocols and reflections. The aim is to show judgement across the full patient journey rather than isolated technical competence.
Clinical pathway evidence
Use current NHS-style evidence from the points where consultant judgement is visible.
Treatment choice and toxicity
Chemotherapy, immunotherapy, targeted therapy, consent, dose modification and response assessment.
Oncological emergencies
Neutropenic sepsis, spinal cord compression, immunotherapy toxicity, hypercalcaemia and deteriorating patients.
Tumour-site decisions
Show your role in integrating imaging, pathology, surgery, SACT, radiotherapy and patient preference.
Complex patient conversations
Consent, prognosis, treatment ceilings, recurrence, survivorship and end of life care.
Evidence your post itself must produce
A Clinical Oncology-friendly post needs to produce current, consultant-observed evidence across radiotherapy and systemic treatment, not just clinic volume.
When assessing whether a post is Portfolio Pathway-friendly, do not stop at the job title. A role called "Locum Consultant Clinical Oncologist" can still be weak if it does not give you radiotherapy planning, peer review, SACT decision making, acute oncology and consultant-observed practice. Equally, a well-designed senior SAS or Specialist post can be very strong if the department actively supports assessment, appraisal, structured reports and evidence collection.
The practical question is whether the job produces evidence you can actually upload. Does the department keep clear MDT records? Can you access treatment plans and peer review outcomes? Are there consultants who will observe and document your work? Do you have acute oncology exposure? Are you involved in audit, QI and governance? These details matter more than the prestige of the title.
The Clinical Oncology job-fit evidence checklist
These are the documents and opportunities your role needs to produce.
A 90-day evidence plan
What to do next
Map all 19 CiPs
Mark each CiP as strong, partial or missing, with the exact evidence you already have.
Audit radiotherapy evidence
Check whether your plans, contours, peer review and toxicity evidence are recent and consultant-observed.
Fill pathway gaps
Target SACT, acute oncology, MDT, inpatient, survivorship, communication and governance gaps.
Brief referees
Ask whether they can comment on the full Clinical Oncology consultant role, not just one tumour site.
Download the Clinical Oncology evidence map
A two-page checklist for radiotherapy, SACT, acute oncology, MDT, appraisal, MSF and structured-report evidence.
Where BDI Consultants fits
BDI Consultants does not sell Portfolio Pathway review packages and this article is not a substitute for GMC or RCR guidance. Our recruitment work is different: we help senior doctors find Consultant, Specialist and senior SAS opportunities where Portfolio Pathway progress is understood rather than ignored.
For Clinical Oncology, that means looking carefully at whether the post gives you radiotherapy, SACT, acute oncology, MDT, governance, appraisal and structured-report evidence.
Official sources used
| Source | Publisher |
|---|---|
| Clinical Oncology Specialty Specific Guidance | General Medical Council |
| Portfolio Pathway in Clinical Oncology | Royal College of Radiologists |
| Clinical Oncology curriculum | General Medical Council / RCR |
Frequently asked
Is Clinical Oncology Portfolio Pathway the same as Medical Oncology?
No. Clinical Oncology in the UK includes both radiotherapy and systemic anti-cancer therapy. Medical Oncology is a separate route focused on systemic cancer medicine, acute oncology, biomarkers, trials and medical management. A Clinical Oncology application must prove radiotherapy capability.
Do Clinical Oncology applicants need FRCR?
FRCR is the UK Clinical Oncology examination and the SSG treats it as the key test of knowledge. Applicants without FRCR need very robust alternative evidence covering the same knowledge and skills. Do not assume senior experience alone replaces exam evidence.
How recent does Clinical Oncology evidence need to be?
The Clinical Oncology SSG says evidence of competence should be recent, and evidence of skills or experience gathered from clinical practice more than five years ago should not be submitted as current competence evidence. Older material can explain background, but current evidence has to prove maintained capability.
What evidence is most important in Clinical Oncology?
A strong application needs evidence across the Clinical Oncology CiPs, including radiotherapy, systemic therapy, acute oncology, MDT work, patient communication, appraisals, MSF, patient feedback, safety, quality improvement and structured reports from referees who know the applicant's current practice.
What kind of Clinical Oncology post is Portfolio Pathway-friendly?
The best post produces tumour-site MDT evidence, radiotherapy planning and delivery, SACT, acute oncology, inpatient or treatment-complication management, governance, audit/QI, patient feedback, MSF and consultants who can observe and report on current practice.
Can a doctor trained overseas apply directly?
It can be difficult if the evidence does not mirror UK Clinical Oncology practice, especially because UK Clinical Oncology includes both radiotherapy and systemic therapies. Overseas evidence may help, but applicants often need recent UK-style evidence before submitting.